FibroBiologics Board Shake-up: New Director Elected, Officer Compensation Noted
Ticker: FBLG · Form: 8-K · Filed: Oct 29, 2024 · CIK: 1958777
Sentiment: neutral
Topics: board-of-directors, executive-compensation, personnel-change
TL;DR
FibroBiologics swapped a director and hinted at executive pay changes.
AI Summary
FibroBiologics, Inc. announced on October 25, 2024, a change in its board of directors. Specifically, the company reported the departure of Director Dr. Jonathan L. R. Roth and the election of Dr. Michael J. Yaszemski as a new director. The filing also noted compensatory arrangements for certain officers, though specific details were not provided in this excerpt.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, while information on officer compensation is crucial for understanding executive incentives and potential dilution.
Risk Assessment
Risk Level: medium — Board changes and unspecified compensatory arrangements introduce a degree of uncertainty regarding future strategic direction and financial commitments.
Key Players & Entities
- FibroBiologics, Inc. (company) — Registrant
- Dr. Jonathan L. R. Roth (person) — Departing Director
- Dr. Michael J. Yaszemski (person) — Newly Elected Director
- October 25, 2024 (date) — Date of earliest event reported
FAQ
Who has been elected to the FibroBiologics, Inc. board of directors?
Dr. Michael J. Yaszemski has been elected as a new director.
Who has departed from the FibroBiologics, Inc. board of directors?
Dr. Jonathan L. R. Roth has departed from the board of directors.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is October 25, 2024.
What other item information is included in this 8-K filing besides director changes?
The filing also includes information on compensatory arrangements of certain officers and other events.
What is the principal executive office address for FibroBiologics, Inc.?
The principal executive office address is 455 E. Medical Center Blvd., Suite 300, Houston, Texas 77598.
Filing Stats: 1,685 words · 7 min read · ~6 pages · Grade level 12.2 · Accepted 2024-10-29 16:01:19
Key Financial Figures
- $0.00001 — ichregistered Common stock, par value $0.00001 per share FBLG Nasdaq Global Marke
- $325,000 — ceive his current annual base salary of $325,000, payable in accordance with the Company
- $45,833 — ffman will receive cash compensation of $45,833 per month, subject to standard withhold
Filing Documents
- form8-k.htm (8-K) — 47KB
- 0001493152-24-042867.txt ( ) — 224KB
- fblg-20241025.xsd (EX-101.SCH) — 3KB
- fblg-20241025_lab.xml (EX-101.LAB) — 33KB
- fblg-20241025_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: October 29, 2024 FibroBiologics, Inc. By: /s/ Pete O'Heeron Name: Pete O'Heeron Title: Chief Executive Officer